{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,4,5]],"date-time":"2022-04-05T03:21:56Z","timestamp":1649128916143},"reference-count":0,"publisher":"Informa UK Limited","license":[{"start":{"date-parts":[[2010,4,1]],"date-time":"2010-04-01T00:00:00Z","timestamp":1270080000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/3.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["TCRM"],"DOI":"10.2147\/tcrm.s7306","type":"journal-article","created":{"date-parts":[[2010,9,10]],"date-time":"2010-09-10T04:18:36Z","timestamp":1284092316000},"page":"183","source":"Crossref","is-referenced-by-count":0,"title":["Critical appraisal of laropiprant and extended-release niacin combination in the management of mixed dyslipidemias and primary hypercholesterolemia"],"prefix":"10.2147","author":[{"family":"Nicholls","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"family":"Hussein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"301","published-online":{"date-parts":[[2010,4]]},"container-title":["Therapeutics and Clinical Risk Management"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.dovepress.com\/getfile.php?fileID=6106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2016,10,30]],"date-time":"2016-10-30T22:00:47Z","timestamp":1477864847000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.dovepress.com\/critical-appraisal-of-laropiprant-and-extended-release-niacin-combinat-peer-reviewed-article-TCRM"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,4]]},"references-count":0,"URL":"https:\/\/doi.org\/10.2147\/tcrm.s7306","relation":{},"ISSN":["1178-203X"],"issn-type":[{"value":"1178-203X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,4]]}}}